CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 501 enrolled
Drug / intervention
Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01425281
NCT01425281N/ACompleted
CompareCT.gov

ABSORB II RANDOMIZED CONTROLLED TRIAL A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions

Abbott Medical Devices·interventional·Posted Aug 30, 2011·Updated Nov 13, 2019

In Brief

A clinical study evaluating Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System and Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System for Coronary Artery Disease. Completed, enrolled 501 participants across 1 site.

Detailed Summary

Prospective, randomized (2:1), active control, single blinded, parallel two-arm, multi-center clinical investigation using Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System (ABSORB BVS); compared to Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System (XIENCE)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesBelgium
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 30, 2011
Enrollment StartNov 1, 2011
Primary CompletionJul 1, 2016
Study CompletionMay 23, 2018
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 14.8 years ago

Interventions

Abbott Vascular XIENCE Everolimus Eluting Coronary Stent Systemdevice

XIENCE implantation in the treatment of coronary artery disease.

Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold Systemdevice

ABSORB BVS implantation in the treatment of coronary artery disease.